Notable Labs, Ltd. (NTBL) - Long-Term Debt to Capital

This chart illustrating the price evolution of Notable Labs, Ltd. (NTBL) highlights business complexities stemming from stringent FDA and CLIA requirements, as well as high development costs for the PPMP AI system, with the metric standing at 0.00. The scaling model relies on cloud-based clinic access to analytics, eliminating the need for facilities to establish their own laboratories. Growth potential is based on the biotech sector's increasing interest in precision therapy forecasting tools.

Notable Labs, Ltd. (NTBL) diversifies its revenue through AI software for pharma behemoths and its own therapeutic developments. By analyzing the long-term debt-to-equity profile on GURU.Markets, an investor can determine the business's degree of reliance on external borrowings. This metric compares liabilities with a maturity of over one year against the company's net assets. This allows for an assessment of financial stability and the risk of excessive leverage. A stable ratio confirms the safety of the expansion strategy.